Hiroshige Yoshioka

16.6k total citations · 2 hit papers
204 papers, 4.5k citations indexed

About

Hiroshige Yoshioka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Hiroshige Yoshioka has authored 204 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Pulmonary and Respiratory Medicine, 153 papers in Oncology and 23 papers in Epidemiology. Recurrent topics in Hiroshige Yoshioka's work include Lung Cancer Treatments and Mutations (159 papers), Lung Cancer Research Studies (89 papers) and Lung Cancer Diagnosis and Treatment (74 papers). Hiroshige Yoshioka is often cited by papers focused on Lung Cancer Treatments and Mutations (159 papers), Lung Cancer Research Studies (89 papers) and Lung Cancer Diagnosis and Treatment (74 papers). Hiroshige Yoshioka collaborates with scholars based in Japan, United States and United Kingdom. Hiroshige Yoshioka's co-authors include Nobuyuki Yamamoto, Takashi Seto, Kazuhiko Nakagawa, Makoto Nishio, Tadashi Ishida, Katsuyuki Kiura, Toyoaki Hida, Nobuyuki Katakami, Tomohide Tamura and Akihiro Nishiyama and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Hiroshige Yoshioka

192 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

2013 449 citations Takashi Seto, Makoto Nishio et al. profile →
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

2017 308 citations Takeharu Yamanaka, Takashi Seto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroshige Yoshioka Japan	37	3.6k	3.2k	940	589	499	204	4.5k
Masahiro Tabata Japan	35	2.9k 0.8×	2.9k 0.9×	1.3k 1.3×	606 1.0×	465 0.9×	225	4.5k
Alessandra Bearz Italy	31	3.1k 0.9×	2.5k 0.8×	772 0.8×	459 0.8×	309 0.6×	176	4.4k
Seiji Niho Japan	37	3.0k 0.8×	3.2k 1.0×	1.1k 1.2×	547 0.9×	894 1.8×	213	5.1k
Akira Inoue Japan	37	5.5k 1.5×	5.0k 1.6×	1.8k 1.9×	930 1.6×	461 0.9×	193	7.1k
Brett Hughes Australia	31	2.1k 0.6×	2.3k 0.7×	820 0.9×	696 1.2×	639 1.3×	179	4.4k
Michael S. Rabin United States	27	2.3k 0.6×	1.9k 0.6×	654 0.7×	419 0.7×	255 0.5×	86	3.2k
John Grous United States	12	2.6k 0.7×	4.1k 1.3×	966 1.0×	431 0.7×	228 0.5×	23	5.1k
Nick Thatcher United Kingdom	34	3.9k 1.1×	4.0k 1.3×	1.5k 1.6×	810 1.4×	434 0.9×	117	5.7k
Coleman K. Obasaju United States	32	3.0k 0.8×	2.3k 0.7×	775 0.8×	427 0.7×	273 0.5×	157	4.1k
Dolores Isla Spain	30	3.1k 0.9×	3.1k 1.0×	1.5k 1.6×	888 1.5×	210 0.4×	202	5.1k

Countries citing papers authored by Hiroshige Yoshioka

Since Specialization

Citations

This map shows the geographic impact of Hiroshige Yoshioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshige Yoshioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshige Yoshioka more than expected).

Fields of papers citing papers by Hiroshige Yoshioka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshige Yoshioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshige Yoshioka. The network helps show where Hiroshige Yoshioka may publish in the future.

Co-authorship network of co-authors of Hiroshige Yoshioka

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshige Yoshioka. A scholar is included among the top collaborators of Hiroshige Yoshioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshige Yoshioka. Hiroshige Yoshioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Casarini, Ignacio, Tibor Csőszi, Mehmet Alı Nahıt Şendur, et al.. (2025). Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Annals of Oncology. 36(7). 775–785. 4 indexed citations

Nosaki, Kaname, Yoshitaka Zenke, T. Sasaki, et al.. (2024). JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8132–TPS8132. 2 indexed citations

Watanabe, Yasutaka, Makoto Nishio, Kadoaki Ohashi, et al.. (2024). J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.. Journal of Clinical Oncology. 42(16_suppl). 8573–8573.

Miyauchi, Eisaku, Kadoaki Ohashi, Atsushi Osoegawa, et al.. (2024). J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan. JTO Clinical and Research Reports. 6(3). 100783–100783.

Ota, Takayo, Yuki Takeyasu, Satoaki Nakamura, et al.. (2024). Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer. Cancers. 16(18). 3127–3127. 1 indexed citations

Watanabe, Kageaki, Keita Sasaki, Ryunosuke Machida, et al.. (2024). High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese Journal of Clinical Oncology. 54(10). 1084–1092. 3 indexed citations

Kogure, Yoshihito, Hiroya Hashimoto, Haruko Daga, et al.. (2024). Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%. JTO Clinical and Research Reports. 6(3). 100784–100784.

Fukushima, Takuya, Jiro Nakano, Kazuki Fujii, et al.. (2024). Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia. Thoracic Cancer. 16(2). e15503–e15503. 1 indexed citations

Sekino, Yuta, Tomoyuki Hishida, Hiroshige Yoshioka, et al.. (2024). Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG). Japanese Journal of Clinical Oncology. 55(2). 176–182.

10.

Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2023). Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers. 15(5). 1543–1543. 7 indexed citations

11.

Ikeda, Y., et al.. (2023). A Case of Radiation Recall Pneumonitis Caused by Nivolumab+Ipilimumab Combination Therapy. Haigan. 63(4). 319–324.

12.

Garon, Edward B., Shun Lü, Yasushi Goto, et al.. (2023). Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. Journal of Clinical Oncology. 42(2). 180–191. 41 indexed citations

13.

Takamori, Shinkichi, Yasushi Yatabe, Atsushi Osoegawa, et al.. (2023). Rare but clinically important salivary gland-type tumor of the lung: A review. Japanese Journal of Clinical Oncology. 54(2). 121–128. 2 indexed citations

14.

Miura, Satoru, Yasuhiro Koh, Koichi Azuma, et al.. (2023). Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC Cancer. 23(1). 6–6. 5 indexed citations

15.

Nishio, Makoto, Shinji Atagi, Kōichi Goto, et al.. (2023). Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer. Translational Lung Cancer Research. 12(6). 1167–1184. 3 indexed citations

16.

Shiotsu, Shinsuke, Akihiro Yoshimura, Tadaaki Yamada, et al.. (2022). Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. Frontiers in Oncology. 12. 904644–904644. 8 indexed citations

17.

Ito, Kentaro, Masahiro Morise, Kazushige Wakuda, et al.. (2021). A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open. 6(3). 100115–100115. 33 indexed citations

18.

Ito, Akihiro, Tadashi Ishida, Hiromasa Tachibana, et al.. (2014). Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone. European Respiratory Journal. 44(Suppl 58). P4696–P4696. 2 indexed citations

19.

Ikeda, Satoshi, Hiroshige Yoshioka, Machiko Arita, et al.. (2014). Interstitial lung disease induced by alectinib (CH5424802/RO5424802). Japanese Journal of Clinical Oncology. 45(2). 221–224. 14 indexed citations

20.

Kawahara, Masaaki, Shinji Atagi, Kiyoshi Komuta, et al.. (2013). Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.. PubMed. 33(10). 4631–7. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact